Patent classifications
A61N2/06
MAGNETIC STIMULATION APPARATUS, METHOD, AND SYSTEM
An apparatus and method configured to generate a magnetic field applied to a target location. The apparatus and method include a magnetic stimulation apparatus, including a permanent magnet configured to generate a magnetic field, and a magnetic shield configured to shield at least one target region from the magnetic field generated by the permanent magnet, wherein the magnetic shield includes at least one gap region configured to expose at least one other target region to the magnetic field generated by the permanent magnet. At least one gap region is moveable so that the shielded at least one target region is exposed to the magnetic field at the other target region.
Pulmonary hypertension treatment
Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).
Pulmonary hypertension treatment
Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).
Magnetically-assisted delivery into and through the skin
A method for treating a patient includes providing a delivery device capable of generating a magnetic field, placing the device above or below the skin, and directing the agent into the patient's skin via the device. The therapeutic agent is directed to a treatment site through the skin. Systems for directing agents are also included herein.
Magnetically-assisted delivery into and through the skin
A method for treating a patient includes providing a delivery device capable of generating a magnetic field, placing the device above or below the skin, and directing the agent into the patient's skin via the device. The therapeutic agent is directed to a treatment site through the skin. Systems for directing agents are also included herein.
Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for treatment of anxiety. Described are methods and devices to treat anxiety that involves no medication. Methods and devices described herein use alternating magnetic fields to gently “tune” the brain and affect symptoms of anxiety.
Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for treatment of anxiety. Described are methods and devices to treat anxiety that involves no medication. Methods and devices described herein use alternating magnetic fields to gently “tune” the brain and affect symptoms of anxiety.
Devices and methods for stimulating the immune system to treat damaged or abnormal tissue using compressed static magnetic fields
The devices and methods of stimulating the immune system to treat damaged and abnormal tissue using compressed static magnetic fields provides for noninvasive treatment of damages tissue and removal of abnormal tissue. At least two magnets are positioned to have their static magnetic fields compressed at the damaged or abnormal tissue and at the immediately surrounding healthy tissue. The compressed static magnetic fields stimulate the immune system in the immediately surrounding healthy tissue which treats the damaged or abnormal tissue. The treated tissue fully regenerates without additional medical intervention. The devices provide for efficient exposure to compressed magnetic fields and ease of use at different locations on a body and different types of animal species.
Devices and methods for stimulating the immune system to treat damaged or abnormal tissue using compressed static magnetic fields
The devices and methods of stimulating the immune system to treat damaged and abnormal tissue using compressed static magnetic fields provides for noninvasive treatment of damages tissue and removal of abnormal tissue. At least two magnets are positioned to have their static magnetic fields compressed at the damaged or abnormal tissue and at the immediately surrounding healthy tissue. The compressed static magnetic fields stimulate the immune system in the immediately surrounding healthy tissue which treats the damaged or abnormal tissue. The treated tissue fully regenerates without additional medical intervention. The devices provide for efficient exposure to compressed magnetic fields and ease of use at different locations on a body and different types of animal species.
Electromagnetic method for in-vivo disruption of viral insults
A therapeutic method of reducing or eliminating viral infections in vivo includes subjecting a virally infected patient to one of a variety of strong magnetic fields. A static magnetic field has a magnetic field intensity of at least about 5 nanoTesla sufficient to be effective to disrupt viral metabolism. An alternating magnetic field has a magnetic field intensity of at least 0.1 nanoTesla sufficient to be effective to disrupt viral metabolism. A method of disrupting viral metabolism includes subjecting an infected patient or a mixture of live host cells and virus to the alternating magnetic field. A virus disruption apparatus includes a magnetic field generator of static or alternating magnetic fields. The magnetic field generator is selected from a Magnetic Resonance Imaging device, at least one permanent magnet, at least one superconducting magnet, at least one solenoid, and any combination thereof.